The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment
This article is a review of epidemiology, pathogenesis and treatment of venous thromboembolism (VTE) in cancer patients. In accordance with actual guidelines, the duration of anticoagulant therapy of cancer-related venous thrombosis should be at least 6 months. The use of vitamin K antagonists (VKA)...
Main Authors: | К. V. Lobastov, I. V. Schastlivtsev |
---|---|
Format: | Article |
Language: | English |
Published: |
Stolichnaya Izdatelskaya Kompaniya
2020-05-01
|
Series: | Racionalʹnaâ Farmakoterapiâ v Kardiologii |
Subjects: | |
Online Access: | https://www.rpcardio.com/jour/article/view/2177 |
Similar Items
-
Direct oral anticoagulants in cancer-associated venous thromboembolism
by: Kirill Lobastov, et al.
Published: (2020-01-01) -
ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN
by: M. Yu. Gilyarov, et al.
Published: (2017-12-01) -
Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis
by: Sobieraj, Diana M., et al.
Published: (2015) -
Fatigue after initiating rivaroxaban for venous thromboembolism
by: Tina Margrethe Karlsvik, et al.
Published: (2020-05-01) -
Anticoagulant therapy for acute venous thromboembolism
by: Hilal Ermiş, et al.
Published: (2017-09-01)